Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBR-760 in Adult Patients with Non-Functioning Pituitary Adenomas
2019-003142-32Phase 2Terminated
- Sponsor
- Tiburio Therapeutics
- Start
- May 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chromophobe adenoma comparing TBR-760 with Placebo (2 arms). Primary endpoint: Safety and tolerability of TBR-760. Started May 2020; status: terminated.
02
Drugs
onzigolide
03
Conditions
chromophobe adenoma
Beyond the preview
Go deeper on 2019-003142-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003142-32.